CD14 and Parkinson disease: In this study, we have tested the effect of the LRRK2 mutations associated with CD and PD using freshly isolated human CD14+ blood monocytes for ex vivo stimulation with IFN-γ under the influence of NFAT-specific inhibitor (FK506) or LRRK2-specific kinase inhibitor (GSK2578215A).